Hasil Pencarian - Mark C Genovese

  • Menampilkan 1 - 15 hasil dari 15
Perbaiki Hasil
  1. 1
    Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies

    Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind... oleh Mark C Genovese, Rieke Alten, Herbert Kellner, Yasumasa Arai, Rafael Muniz

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States

    The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients... oleh Robin K. Dore, Jenya N. Antonova, Chakkarin Burudpakdee, Lawrence Chang, Magdaliz Gorritz, Mark C. Genovese

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

    Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis oleh Bernard Combe, Proton Rahman, Hideto Kameda, Juan D. Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C. Genovese

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies

    Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies oleh Mark C. Genovese, Patrick Durez, Roy Fleischmann, Yoshiya Tanaka, Daniel Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis

    Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis oleh Anne C. Bay-Jensen, Adam Platt, Martin A. Jenkins, Michael E. Weinblatt, Inger Byrjalsen, Kishwar Musa, Mark C. Genovese, Morten A. Karsdal

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis

    Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis oleh Edward Keystone, Josef S Smolen, Paul Emery, Mark C Genovese, Michael E Weinblatt, Jung-Yoon Choe, Gihyun Myung, Evelyn Hong, Inyoung Baek, Jeehoon Ghil

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

    Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis oleh Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

    Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase... oleh Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K. Mangan, Gerd R. Burmester

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

    Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis oleh Josef S. Smolen, Young Mo Kang, Wan-Hee Yoo, Paul Emery, Michael E. Weinblatt, Edward C. Keystone, Mark C. Genovese, Gihyun Myung, Inyoung Baek, Jeehoon Ghil

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials

    Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials oleh Mark C. Genovese, Gerd R. Burmester, Owen Hagino, Karthinathan Thangavelu, Melitza Iglesias-Rodriguez, Gregory St John, Miguel A. González-Gay, Thomas Mandrup-Poulsen, Roy Fleischmann

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

    FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension oleh Mark C. Genovese, Josephine Glover, Maria Greenwald, Wieslawa Porawska, Elias Chalouhi El Khouri, Eva Dokoupilova, Juan Ignacio Vargas, Mykola Stanislavchuk, Herbert Kellner, Elena Baranova, Nobuhito Matsunaga, Rieke Alten

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis

    Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis oleh Gerd Burmester, Tsutomu Takeuchi, Josef S Smolen, Mark C Genovese, Masayoshi Harigai, Kevin Winthrop, Yi-Ming Chen, Tsu-Yi Hsieh, Chad Walls, Wen-Shuo Wu, Christina Dickson, Ran Liao

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA

    Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA oleh Christine Radawski, Mark C. Genovese, Brett Hauber, W. Benjamin Nowell, Kelly Hollis, Carol L. Gaich, Amy M. DeLozier, Kelly Gavigan, Maria Reynolds, Anabela Cardoso, Jeffrey R. Curtis

    Diterbitkan 2019-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

    Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study oleh Mark C. Genovese, Maria W. Greenwald, Sergio R. Gutierrez-Ureña, Mario H. Cardiel, Jeffrey E. Poiley, Anna Zubrzycka-Sienkiewicz, Christine E. Codding, Annie Wang, Weizhong He, Rebecca Amos, Raul Vinueza, Xuegong Wang, Jay P. Garg, Alan J. Kivitz

    Diterbitkan 2019-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.

    Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. oleh Jason Ptacek, Rachael E Hawtin, Dongmei Sun, Brent Louie, Erik Evensen, Barbara B Mittleman, Alessandra Cesano, Guy Cavet, Clifton O Bingham, Stacey S Cofield, Jeffrey R Curtis, Maria I Danila, Chander Raman, Richard A Furie, Mark C Genovese, William H Robinson, Marc C Levesque, Larry W Moreland, Peter A Nigrovic, Nancy A Shadick, James R O'Dell, Geoffrey M Thiele, E William St Clair, Christopher C Striebich, Matthew B Hale, Houman Khalili, Franak Batliwalla, Cynthia Aranow, Meggan Mackay, Betty Diamond, Garry P Nolan, Peter K Gregersen, S Louis Bridges

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: